UM  > Faculty of Health Sciences
Extract of Ginkgo biloba for Tardive Dyskinesia: Meta-analysis of Randomized Controlled Trials
Zheng W.5; Xiang Y.-Q.7; Ng C.H.3; Ungvari G.S.4; Chiu H.F.K.6; Xiang Y.-T.1
Source PublicationPharmacopsychiatry
ISSN14390795 01763679

Objective: Free radicals may be involved in the pathogenesis of tardive dyskinesia (TD). We conducted this meta-analysis to systematically examine the efficacy of extract of Ginkgo biloba (EGb), a potent antioxidant possessing free radical-scavenging properties, as a treatment for TD in schizophrenia using randomized controlled trial (RCT) data. Method: Drawn from English and Chinese databases, 3 RCTs of EGb augmentation of antipsychotics (APs) vs. AP plus placebo or AP monotherapy were identified. 2 evaluators extracted data. The primary outcome measure was the severity of TD symptoms assessed by the Abnormal Involuntary Movement Scale (AIMS). Weighted mean difference (WMD) and risk ratio (RR) ±95% confidence intervals (CI) were calculated. Statistical analyses were performed using Review Manager (version and STATA (version 12.0). Results: The 3 RCTs (n=299) from China, of 12 weeks duration, involved schizophrenia patients with TD of 55.9±13.4 years old. EGb (240 mg/day) outperformed the control group in reducing the severity of TD and clinical symptoms as measured by the AIMS (trials=3, n=299, WMD: -2.30 (95%CI: - 3.04, -1.55), P<0.00001) and the adverse drug reactions as assessed by the Treatment Emergent Symptom Scale (TESS) (trials=2, n=142, WMD: -2.38 (95%CI: -4.01, -0.74), P=0.004). Both the Positive and Negative Syndrome Scale (PANSS) total score (trials=2, n=239, P=0.87) and all-cause discontinuation (trials=3, n=299, P=0.21) were similar between the EGb and control group. Conclusion: This meta-analysis suggests that adjunctive EGb appeared to be an effective and safe option for improving TD in the treatment of schizophrenia patients. However, better RCTs are needed to demonstrate its efficacy and safety especially on cognitive function in TD. Trial registration: PROSPERO: CRD42015024930

KeywordAntipsychotic Ginkgo Biloba Meta-analysis Tardive Dyskinesia
URLView the original
Indexed BySCIE
WOS Research AreaPharmacology & Pharmacy ; Psychiatry
WOS SubjectPharmacology & Pharmacy ; Psychiatry
WOS IDWOS:000376659400003
Fulltext Access
Citation statistics
Cited Times [WOS]:17   [WOS Record]     [Related Records in WOS]
Document TypeJournal article
CollectionFaculty of Health Sciences
Affiliation1.Universidade de Macau
2.Beijing An Ding Hospital, Capital Medical University
3.University of Melbourne
4.University of Western Australia
5.Guangzhou Medical University
6.Chinese University of Hong Kong
7.Capital Medical University, Beijing Institute For Brain Disorders
Recommended Citation
GB/T 7714
Zheng W.,Xiang Y.-Q.,Ng C.H.,et al. Extract of Ginkgo biloba for Tardive Dyskinesia: Meta-analysis of Randomized Controlled Trials[J]. Pharmacopsychiatry,2016,49(3):107-111.
APA Zheng W.,Xiang Y.-Q.,Ng C.H.,Ungvari G.S.,Chiu H.F.K.,&Xiang Y.-T..(2016).Extract of Ginkgo biloba for Tardive Dyskinesia: Meta-analysis of Randomized Controlled Trials.Pharmacopsychiatry,49(3),107-111.
MLA Zheng W.,et al."Extract of Ginkgo biloba for Tardive Dyskinesia: Meta-analysis of Randomized Controlled Trials".Pharmacopsychiatry 49.3(2016):107-111.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Zheng W.]'s Articles
[Xiang Y.-Q.]'s Articles
[Ng C.H.]'s Articles
Baidu academic
Similar articles in Baidu academic
[Zheng W.]'s Articles
[Xiang Y.-Q.]'s Articles
[Ng C.H.]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Zheng W.]'s Articles
[Xiang Y.-Q.]'s Articles
[Ng C.H.]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.